InsidersTradesSigma
Track the PTC Therapeutics, INC. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, PTC Therapeutics, INC. has logged 379 insider filings. Market capitalisation: €6.1bn. The latest transaction was reported on 28 August 2026 (Cession). Among the most active insiders: Almstead Neil Gregory. The full history is free.
PTC Therapeutics, INC. has reported a total of 86 insider trading declarations in the last 90 days, with a total selling amount of approximately 29,934,392 EUR and no reported buying activity. The top insider by total amount sold is Almstead Neil Gregory, the Chief Technical Officer, with sales totaling approximately 13,509,617 EUR from 40 declarations. Other notable insiders include Section Six Partners, L.P., an affiliate of a director, and Michael Schmertzler, a director, each with sales of approximately 3,151,775 EUR from one declaration each. Recent notable sales include Section Six Partners, L.P. and Michael Schmertzler, both reporting sales on August 19 and August 25, 2026, respectively. Almstead Neil Gregory has multiple sales recorded in June and July 2026, including amounts of 1,911,390 EUR and 1,681,465 EUR.
Auto-generated summary, refreshed daily.Updated 1d ago
379
Insider Decl.
n/a
Thresholds
€184,586
1 ops.
Buy Volume
€28m
197 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate PTC Therapeutics, INC. Buy (bullish), based on 14 analysts. Average price target: US$99.29.
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,362 of 29,020 companies
75.7
score / 100
Value76
Quality76
FCF yld7.0%
Earn yld12%
EV/EBITDA9.6x
ROE·
Gross mgn97%
Net mgn39%
Debt/EBITDA3.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations379 total
6,874 shares@ US$72.74Common StockSEC:0001288952-26-000006:0
5,626 shares@ US$73.18Common StockSEC:0001288952-26-000006:1
11,890 shares@ US$71.55Common StockSEC:0001288952-26-000006:2
610 shares@ US$72.22Common StockSEC:0001288952-26-000006:3
50,000 shares@ US$73.000.060% mcap100.0% of flowCommonSEC144:0001628280-26-058901
5,335 shares@ US$72.860.0067% mcap14.8% of flowCommon StockSEC:0001288952-26-000004:0
7,165 shares@ US$73.670.0091% mcap20.1% of flowCommon StockSEC:0001288952-26-000004:1
9,419 shares@ US$70.780.011% mcap25.2% of flowCommon StockSEC:0001288952-26-000004:2
2,390 shares@ US$71.880.0029% mcap6.5% of flowCommon StockSEC:0001288952-26-000004:3
691 shares@ US$72.920.0009% mcap1.9% of flowCommon StockSEC:0001288952-26-000004:4
50,000 shares@ US$73.000.061% mcap100.0% of flowCommonSEC144:0001628280-26-058006
2,813 shares@ US$25.690.0012% mcap0.8% of flowCommon StockSEC:0001578852-26-000022:0
1,844 shares@ US$72.390.0022% mcap1.4% of flowCommon StockSEC:0001578852-26-000022:1
969 shares@ US$72.900.0012% mcap0.7% of flowCommon StockSEC:0001578852-26-000022:2
2,813 shares@ US$71.700.0033% mcap2.2% of flowCommonSEC144:0001959173-26-006063
10,292 shares@ US$68.570.012% mcap14.5% of flowCommon StockSEC:0001808968-26-000017:0
10,292 shares@ US$68.57310.012% mcap17.0% of flowCommonSEC144:0001959173-26-005607
4,000 shares0Common StockSEC:0002142653-26-000004:0
2,000 shares0Common StockSEC:0002142653-26-000004:1
3,494 shares@ US$80.350.0044% mcap20.1% of flowCommon StockSEC:0001984065-26-000008:0
3,494 shares@ US$80.34710.0044% mcap25.1% of flowCommonSEC144:0001959173-26-005220
2,464 shares@ US$46.540.0016% mcap0.5% of flowCommon StockSEC:0001578850-26-000023:0
2,464 shares@ US$90.250.0031% mcap0.9% of flowCommon StockSEC:0001578850-26-000023:1
10,000 shares@ US$42.950.0061% mcap12.2% of flowCommon StockSEC:0001866044-26-000005:0
10,000 shares@ US$90.000.013% mcap25.5% of flowCommon StockSEC:0001866044-26-000005:1
25 of 379 declarations
About PTC Therapeutics, INC.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a U.S.-listed biopharmaceutical company headquartered in Warren, New Jersey, United States. For international investors, PTC is best understood as a rare-disease specialist with a commercial and R&D franchise focused on neurology and metabolic disorders. The company was founded in the late 1990s; SEC records show a name change date of 1998, consistent with its long operating history in rare-disease drug development. Over time, PTC has built a portfolio designed around high-unmet-need indications, where clinical differentiation and regulatory execution can be more important than broad primary-care scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai)) PTC’s current investment case is driven by a combination of marketed products and a diversified pipeline. Its commercial portfolio has historically included Emflaza (deflazacort) and Translarna (ataluren), both important in the rare-disease space, although those franchises have faced headwinds from generic competition in Emflaza and adverse regulatory developments in Europe for Translarna. More recently, the company has expanded its growth platform with Sephience (sepiapterin) for phenylketonuria, or PKU. Sephience received key approvals in 2025 in the United States, the European Economic Area, and Japan, followed by approval in Brazil in February 2026. PTC also markets Upstaza/Kebilidi in certain geographies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm?utm_source=openai)) From a competitive perspective, PTC occupies a niche position among rare-disease biopharma peers: it is neither a large diversified pharma company nor a pure early-stage research story. Instead, it combines commercial execution with deal-making and royalty monetization. A major recent event was the December 2025 sale of the remainder of its Evrysdi royalty stream to Royalty Pharma, while retaining certain milestone rights tied to Roche sales performance. Another key milestone was the Novartis collaboration on votoplam for Huntington’s disease, which drove a large amount of collaboration and license revenue in 2025 and added strategic optionality to the pipeline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm)) Geographically, PTC has a global footprint across North America, Europe, and parts of Asia, and management has indicated that Sephience could expand to 20 to 30 countries by the end of 2026. The company’s principal executive offices are in Warren, New Jersey, and its public filings and corporate communications confirm its U.S. listing on the NASDAQ market. For investors, PTC offers exposure to rare-disease commercialization, regulatory catalysts, and launch execution, but also carries typical biotech risks tied to reimbursement, competition, and trial outcomes. Recent financial updates show meaningful product-revenue momentum from Sephience, even as legacy products remain under pressure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219xex99d1.htm))
